Drug intelligence / Profile preview

mebendazole

Development stage
Approved
Lead developer
Johnson & Johnson
Modality
Small Molecules
Administration
Oral
01

Overview

Mebendazole is a broad-spectrum anthelmintic drug used to treat a variety of intestinal worm infections, including pinworm (Enterobius vermicularis), whipworm (Trichuris trichiura), roundworm (Ascaris lumbricoides), and hookworm (Ancylostoma duodenale, Necator americanus)[1][2][3][5][6]. It works by inhibiting the formation of microtubules in parasitic worms, which disrupts glucose uptake and depletes their energy stores, ultimately leading to their death[1][6][8]. Mebendazole is poorly absorbed from the gastrointestinal tract and acts primarily within the gut. It is available as chewable tablets or oral suspension for both adults and children. The drug was originally developed by Janssen Pharmaceutica[5].

Brand names
EmvermVermox
Other names
MBZ-Cmebendazole form Cmebendazole crystalline form C
02

Targets

HSP90AA1 (Heat shock protein HSP90-alpha)TUBB (Tubulin (alpha and beta subunits))ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase)

Beyond the preview

Go deeper on mebendazole.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on mebendazole.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call